Therapy for lyme arthritis: Strategies for the treatment of antibiotic-refractory arthritis

Arthritis and Rheumatism

Volumn 54, Issue 10, 2006, Pages 3079-3086

  Steere, Allen C ^a   Angelis, Sheryn M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIBIOTIC THERAPY; ARTHROSCOPY; HUMAN; LYME DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYNOVECTOMY;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BORRELIA BURGDORFERI; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; HUMANS; HYDROXYCHLOROQUINE; LYME DISEASE;

EID: 33750334242     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22131     Document Type: Review

References (48)

1. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest 2004;113:1093-101.
2. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987;107:725-31.
3. Steere AC, Green J, Schoen RT, Taylor E, Hutchinson GJ, Rahn DW, et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 1985;312:869-74.
4. Dattwyler RJ, Halperin JJ, Pass H, Luft BJ. Ceftriaxone as effective therapy for refractory Lyme disease. J Infect Dis 1987; 155:1322-5.
5. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis: randomized comparison of ceftriaxone and penicillin. Lancet 1988;1:1191-4.
6. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 2005;117: 393-7.
7. Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH III, Liu NY, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994;37: 878-88.
8. Coblyn JS, Taylor P. Treatment of chronic Lyme arthritis with hydroxychloroquine. Arthritis Rheum 1981;24:1567-9.
9. Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 1991;34:1056-60.
10. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, et al, for the Infectious Diseases Society of America. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000;31 Suppl 1:1-14.
11. Eckman MH, Steere AC, Kalish RA, Pauker SG. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. N Engl J Med 1997;337:357-63.
12. Steere AC, Duray PH, Butcher EC. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis: comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 1988;31:487-95.
13. Akin E, Aversa J, Steere AC. Expression of adhesion molecules in synovia in patients with treatment-resistant Lyme arthritis. Infect Immun 2001;63:1774-80.
14. Malawista SE. Resolution of Lyme arthritis, acute or prolonged: a new look. Inflammation 2000;24:493-504.
15. Steere AC, Glickstein, L. Elucidation of Lyme arthritis. Nature Rev Immunol 2004;4:143-52.
16. Snydman DR, Schenkein DP, Berardi VP, Lastavica CC, Pariser KM. Borrelia burgdorferi in joint fluid in chronic Lyme arthritis. Ann Intern Med 1986;104:798-800.
17. Schmidli J, Hunziker T, Moesli P, Schaad UB. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis 1988;158: 905-6.
18. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid in Lyme arthritis. N Engl J Med 1994;330:229-34.
19. Bradley JF, Johnson RC, Goodman JL. The persistence of spirochetal nucleic acids in active Lyme arthritis. Ann Intern Med 1994;120:487-9.
20. Priem S, Burmester GR, Kamradt T, Wolbart K, Rittig MG, Krause A. Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis 1998;57:118-21.
21. Carlson D, Hernandez J, Bloom BJ, Coburn J, Aversa JM, Steere AC. Lack of Borrelia burgdorferi DNA in synovial samples in patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 1999;42:2705-9.
22. Pavia C, Inchiosa MA Jr, Wormser GP. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob Agents Chemother 2002;46:132-4.
23. Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J Infect Dis 2002;186: 1430-7.
24. Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study. J Infect Dis 2000;181:1069-81.
25. Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med 1990;323:219-23.
26. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006;203:961-71.
27. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30: 1205-13.
28. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-6.
29. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998;281:703-6.
30. Chen J, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer-surface protein A (OspA) of Borrelia burgdorferi. Arthritis Rheum 1999;42: 1813-22.
31. Meyer AL, Trollmo C, Crawford F, Marrack P, Steere AC, Huber BT, et al. Direct enumeration of Borrelia-reactive CD4+ T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci U S A 2000;97:11433-8.
32. Drouin EE, Glickstein LJ, Steere AC. Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. J Autoimmun 2004;23: 281-92.
33. Ausubel LJ, O'Connor KC, Baecher-Allen C, Trollmo C, Kessler B, Hekking B, et al. Characterization of in vivo expanded OspA-specific human T-cell clones. Clin Immunol 2005;115:313-22.
34. Trollmo C, Meyer AL, Steere AC, Hafler DA, Huber BT. Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1 alpha L is a partial agonist for outer surface protein A-reactive T cells. J Immunol 2001;166:5286-91.
35. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 2003;48:534-40.
36. Shin JJ, Glickstein LJ, Steere AC. Sustained, high levels of pro-inflammatory chemokines and cytokines in joint fluid and synovial tissue during the course of antibiotic-refractory Lyme arthritis [abstract]. Arthritis Rheum 2006. In press.
37. Fawcett PT, Rose CD, Maduskuie VL, Sanderson JJ, Stanek PA, Stetson T, et al. Patients with antibiotic resistant Lyme arthritis have elevated synovial fluid levels of TNF-α [abstract]. Arthritis Rheum 2005;52 Suppl 9:S97.
38. Wharton M, Chorba TL, Vogt RL, Morse DL, Buehler JW. Case definitions for public health surveillance. MMWR Reccom Rep 1990;39(RR-13):1-43.
39. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993; 167:392-400.
40. Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995;44:590-1.
41. Malawista SE, Barthold SW, Persing DH. Fate of B. burgdorferi DNA in tissue of infected mice after antibiotic treatment. J Infect Dis 1994;170:1312-6.
42. Fallon BA, Sackeim HA, Keilp J, Corbera K, Petkova E, Slavov I, et al. Double-blind, placebo-controlled retreatment with IV ceftriaxone for Lyme encephalopathy: clinical outcome [abstract]. In: Proceedings of the 10th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases. Medical University of Vienna, Vienna, Austria, September 11-15, 2005. p. 196.
43. Cimmino MA, Sambri V, Massaria F, Accardo S. An in vitro study of the susceptibility of Borrelia burgdorferi to hydroxychloroquine sulfate. Clin Exp Rheumatol 1994;12:461-2.
44. Brorson O, Brorson, SH. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine. Int Microbiol 2002;5:25-31.
45. Fox RI. Mechanisms of action of hydroxychloroquine as an anti-rheumatic drug. Sem Arthritis Rheum 1993;23:82-91.
46. Pachner AR, Dail D, Bai YB, Sondey M, Pak L, Narayan K, et al. Genotype determines phenotype in experimental Lyme borreliosis. Ann Neurol 2004;56:361-70.
47. Lawson JP, Steere AC. Lyme arthritis: radiologic findings. Radiology 1985;154:37-43.
48. Behera AK, Hildebrand E, Szafranski J, Hung HH, Grodzinsky AJ, Lafyatis R, et al. Role of aggrecanase-1 in Lyme arthritis. Arthritis Rheum 2006;54:3319-29.